Business Wire

NY-GENESIS

27.1.2022 15:02:10 CET | Business Wire | Press release

Share
Genesis Q4 Report Highlights Key Trends from 2021 in Crypto Lending, Trading and Custody

Genesis , a digital asset industry pioneer and digital currency prime brokerage, today released its Q4 2021 Market Observations Report, which provides detail on the company’s growth over the past quarter and the whole year. This growth highlights major trends across institutional digital asset markets, including the continued diversification of digital asset investments, the deepening sophistication of institutional investors entering the crypto market, new types of institutions participating in the market, increasing allocations from managers of diversified portfolios and the growing need for multi-service institutional prime brokerages.

Q4 2021 marked Genesis’ strongest quarter to date, with approximately $102 billion in transactional volume, cementing a year of significant growth across all of its business lines. Highlights during the quarter across crypto lending, trading and custody include the following:

  • Loan originations reached $50 billion, up 40% over Q3 2021. Loan originations for 2021 totaled $131 billion, nearly 7x higher than 2020.
  • Spot trading volume totaled $30.8 billion, up 23% from Q3. For the full year 2021, Genesis’ spot trading volumes increased nearly 6x over 2020 to $116.5 billion.
  • Derivatives notional volume traded was $20.7 billion during the quarter, an increase of 62% compared with Q3. Total notional value traded for the year grew to $53.8 billion, more than 9x over 2020.
  • Onboarded Custody clients grew 53% from the previous quarter.
  • Genesis’ headcount expanded 22% during the quarter to reach 170 employees, spread across three continents.

“2021 was a pivotal year for the crypto industry, and one that demonstrated the merits of smart tactical trading around a core position,” said Michael Moro, CEO of Genesis. “As this asset class continues to mature, driven by increasing institutional participation and growing regulatory clarity, we believe that taking a comprehensive approach to portfolio management will only become more important, and we look forward to achieving new milestones on behalf of our clients in 2022.”

Crypto Lending

Genesis’ lending desk remains the largest crypto lender in the industry and finished the year with over $150 billion in cumulative originations since its launch in March of 2018. Genesis executed a record $50 billion in new originations in Q4 alone, a 40% increase from the previous quarter, and marked the desk’s fifteenth consecutive quarter of growth. Active loans outstanding climbed to $12.5 billion to close the quarter, up 12.3% from Q3. Loans outstanding peaked at over $16 billion in mid-November before seeing a wave of year-end deleveraging as prices on most cryptocurrencies fell.

Over the quarter, the lending desk saw that while demand from clients engaging with DeFi platforms is still strong, focus has shifted towards layer-1 (L1) alternatives, resulting in slightly higher originations in those coins.

Derivatives and Spot Trading

Genesis saw another record quarter in derivatives trading activity with $20.7 billion in notional value traded globally, a 62% quarter-on-quarter growth and a 360% increase over Genesis’ results in Q4 2020. This brings trading activity for 2021 to $53.8 billion in notional volume, an 812% increase over 2020. In December, Genesis also printed the first ever ETH Micro futures trade on the CME and was #1 in market share for blocked BTC and ETH exchange-cleared options via Paradigm, with over $1.5 billion traded.

The Genesis spot desk traded $30.8 billion in volume in Q4, delivering the second-best quarter in the desk’s long history, as well as an increase of 23% over the prior quarter and a 279% increase over Q4 of 2020. Total spot trading volume for the year reached $116.5 billion, a 463% increase over 2020.

Custody

Genesis Custody closed 2021 with a 53% increase in the number of customers onboarded from Q3. The business also reached two critical milestones during Q4 一 Genesis Custody was approved by the Financial Conduct Authority (FCA) as a cryptoasset business, signifying its strong controls, governance and compliance frameworks to counter financial crime, and it completed the System and Organization Controls (SOC) 2 Type 1 examination.

Over the course of Q4, Genesis Custody also began staking assets for clients. The business has taken steps to continue to expand its portfolio of services offered, and to better integrate custody into its clients’ trading and portfolio management workflows.

The Genesis Q4 2021 Market Observations Report provides a comprehensive look into key market activity through insights from the firm’s spot trading, derivatives trading, lending, custody, treasury and prime brokerage businesses. To read the full Q4 2021 Market Observations Report, click here .

About Genesis

Genesis is a full-service digital currency prime brokerage providing a single point of access for select qualified individuals and global institutional investors. Genesis combines unrivaled operational excellence, a seamless user experience, and best-in-class client service to provide the full suite of services global investors require to manage their digital asset portfolios.

The firm offers sophisticated market participants a fully integrated platform to trade, borrow, lend, and custody digital assets, creating new opportunities for yield while increasing capital efficiency for counterparties.

Genesis is a wholly owned subsidiary of Digital Currency Group (DCG) , one of the largest private investors in blockchain and digital asset companies.

For more information on Genesis, please visit genesistrading.com and follow @GenesisTrading on Twitter.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye